Vote Now
Research Grants - 2006


Alzheimer's Assocation Research only
All of alz.org
  • Go to Alz.org
  • Research Center
  • AAIC
  • ISTAART
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Home
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2006


To view an abstract, select an author from the vertical list on the left.

2006 Grant - Small

Retromer-Mutant Mice as a Model of Late-Onset Alzheimer's Disease

Scott A. Small, M.D.
Columbia University Medical Center
New York, New York

2006 Investigator-Initiated Research Grant

The retromer complex is a network of proteins that transports other proteins from one part of a cell to another. Research has shown that this network may not function properly in late-onset Alzheimer's disease, the more common form of the disease that usually affects older people. During late-onset Alzheimer's, two vital components of the retromer complex, known as vacuolar protein-sorting protein 26 (VPS26) and vacuolar protein-sorting protein 35 (VPS35), may become deactivated.

In healthy cultured cells, the retromer complex transports the amyloid precursor protein (APP) from one cellular compartment called the endosome to another compartment. In studies of laboratory cells, Scott A. Small, M.D., and colleagues observed that when the retromer complex does not function properly, APP accumulates in the endosome. This lack of APP transport resulted in elevated levels of beta-amyloid, a protein fragment clipped from APP that may be a key toxic factor in Alzheimer's disease.

To explore this phenomenon in a living model, Dr. Small's team genetically engineered mice to deactivate the VPS26 and VPS35 proteins of the retromer complex. In preliminary studies, the researchers found that these mice produced high levels of beta-amyloid in their brains and experienced certain forms of memory loss. When these mice were bred with mice engineered to produce human mutated APP, the resulting offspring developed still higher levels of accumulated beta-amyloid.

Dr. Small's team will more completely study cellular properties, disease pathology and behavioral deficits in these mice in order to characterize how the dysfunction in APP transport results in increased beta-amyloid production. This work may shed new light on cellular events that contribute to late-onset Alzheimer's and suggest new therapeutic strategies for further investigation.